Johnson & Johnson acquired Neutrogena for approximately $924 million, or $35.25 per share in cash (roughly a 63% premium), through a cash tender offer and subsequent merger in 1994. The acquisition added the dermatologist-recommended skin-care brand to J&J's consumer-health portfolio.